Diag2Tec – Preclinical CRO in Multiple Myeloma, Lymphoma, Leukemia
  • Home
  • Our Expertise
    • Multiple Myeloma
    • Hematological Cancer Cell Lines from Patients
    • Primary Samples from Hematological Malignancies
    • In Vitro Model of Human Plasma Cell Differentiation
    • Flow Cytometry
    • NGS – Biomarkers – New Therapeutic Targets Identification
  • Preclinical Services
    • In vitro Drug Testing
    • Immunotherapies : Assays and Analyses
    • Prognosis and Predictive Biomarkers
  • About us
    • Team & History
    • Prospects and Partners
    • ISO 9001: 2015 Certification
  • Press & Events
    • List of Publications and Patents
    • Diag2Tec Publications and Posters
    • Meet our team
  • Contact
    • Contact us
    • Opportunities
logo

Sitemap

Home → Diag2Tec – Preclinical CRO in MM, Lymphoma, Leukemia → Sitemap

Site Feeds

  • Main RSS Feed
  • Comments RSS Feed

Pages

  • About us
    • ISO 9001: 2015 Certification
    • Prospects and Partners
    • Team & History
  • ChimioFx : Multiple Myeloma Precision Medicine tests
  • Contact & Job opportunities
  • Cookie Policy (EU)
  • Diag2Tec – Preclinical CRO in MM, Lymphoma, Leukemia
    • Sitemap
  • Legal Notice & Confidentiality
  • Meet our team
  • Our Expertise
    • Flow Cytometry
    • Hematological Cancer Cell Lines from Patients
    • In Vitro Model of Human Plasma Cell Differentiation
    • Multiple Myeloma
    • NGS – Biomarkers – New Therapeutic Targets Identification
    • Primary Samples from Hematological Malignancies
  • Our News
  • Preclinical Services
    • Immunotherapies : Assays and Analyses
    • In Vitro Drug Testing
    • Prognosis and Predictive Biomarkers

Categories

  • News
  • Publications

Monthly Archives

  • January 2024
  • February 2019
  • November 2018
  • May 2018
  • February 2018
  • December 2017
  • June 2017
  • July 2016
  • May 2016
  • November 2015
  • June 2015
  • February 2013

Tags

  • Publications

All Articles

  1. Diag2Tec Publications and Posters
    26-Jan-24 • Diag2Tec Admin • 0 Comment
  2. The publication’s team in the front cover of Theranostics journal
    5-Feb-19 • Angélique Bruyer • 0 Comment
  3. Diag2Tec s’attaque au myélome multiple
    14-Nov-18 • admin • 0 Comment
  4. Diag2Tec présente son pitch aux investisseurs lors du salon Occitanie Invest
    10-Nov-18 • admin • 0 Comment
  5. List of Publications and Patents
    5-Nov-18 • admin • 0 Comment
  6. BioPharlAnalyses
    28-May-18 • admin • 0 Comment
  7. Montpellier’s BIC
    2-Feb-18 • admin • 0 Comment
  8. 2017 Annual Congress of American Society of Hematology
    9-Dec-17 • admin • 0 Comment
  9. Midi Libre Newspaper
    28-Jun-17 • admin • 0 Comment
  10. Diag2Tec lauréat du concours i-Lab
    28-Jul-16 • admin • 0 Comment
  11. i-Lab 2016 : Catégorie Création-développement
    25-Jul-16 • admin • 0 Comment
  12. Diag2Tec visit in Florida
    23-May-16 • admin • 0 Comment
  13. Interview of Jerome Moreaux, Diag2Tec’s CSO
    4-Nov-15 • admin • 0 Comment
  14. Diag2Tec soutenue par Crealia
    18-Jun-15 • admin • 0 Comment
  15. Jérôme Moreaux Lauréat Chercheur D’avenir 2013
    5-Feb-13 • Angélique Bruyer • 0 Comment

Diag2Tec’s Headquarters

Immeuble le Stratège
1095 rue Henri Becquerel
34000 Montpellier FRANCE

Diag2Tec’s Laboratories

CHU St Eloi, Dpt Hematology Biology
80 Av Augustin Fliche
34295 Montpellier FRANCE
Diag2Tec logo

  Contact us

Documentation

Services brochure
Publications and Patents
ISO 9001 Certification

Preclinical Services

In vitro Drug Testing
Immunotherapies : Assays and Analysis
Prognosis and Predictive Biomarkers
© Diag2Tec all rights reserved - Legal Notice & Confidentiality - Cookie policy
Back to Top
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}